From our bioinformatics enrichments of KIFs, MSX1 showed potency in functioning as a therapeutic target for breast cancer treatment by generally repressing the expression of survival-related KIFs, which may need further tests in both pharmaceutical development and clinical trials. Here, MSX1 is linked to breast cancer.